454 related articles for article (PubMed ID: 11678474)
21. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386
[TBL] [Abstract][Full Text] [Related]
22. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
[TBL] [Abstract][Full Text] [Related]
23. Drug resistance mutations during structured treatment interruptions.
Yerly S; Fagard C; Günthard HF; Hirschel B; Perrin L;
Antivir Ther; 2003 Oct; 8(5):411-5. PubMed ID: 14640388
[TBL] [Abstract][Full Text] [Related]
24. Predicting antiretroviral drug resistance from the latest or the cumulative genotype.
Garcia F; Alvarez M; Fox Z; Garcia-Diaz A; Guillot V; Johnson M; Chueca N; Phillips A; Hernández-Quero J; Geretti AM
Antivir Ther; 2011; 16(3):373-82. PubMed ID: 21555820
[TBL] [Abstract][Full Text] [Related]
25. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
[TBL] [Abstract][Full Text] [Related]
26. Antiretroviral Resistance Mutations (revised April 2001).
;
HIV Clin Trials; 2001; 2(4):346-55. PubMed ID: 11590539
[No Abstract] [Full Text] [Related]
27. Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.
Winters MA; Merigan TC
Antimicrob Agents Chemother; 2005 Jul; 49(7):2575-82. PubMed ID: 15980322
[No Abstract] [Full Text] [Related]
28. Case report of a novel amino acid deletion in codon 67 and T69G substitution in the reverse transcriptase of HIV-1.
Giri J; Rueda HJ; Monticelli A; Planes N
Antivir Ther; 2000 Sep; 5(3):227-8. PubMed ID: 11075943
[No Abstract] [Full Text] [Related]
29. Differences between semen and plasma of nucleoside reverse transcriptase resistance mutations in HIV-infected patients, using a rapid assay.
Liuzzi G; Chirianni A; Zaccarelli M; Zinzi D; Esposito V; Guadagnino V; Antinori A; Piazza M
In Vivo; 2004; 18(4):509-12. PubMed ID: 15369193
[TBL] [Abstract][Full Text] [Related]
30. Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.
Sabin CA; Wilkins E; Murphy M; Fisher M; de Ruiter A; Easterbrook PJ; Leen C; Vlahakis E; Cane PA; Li X; Pillay D;
Antivir Ther; 2003 Aug; 8(4):301-8. PubMed ID: 14518699
[TBL] [Abstract][Full Text] [Related]
31. The K65R mutation in HIV-1 reverse transcriptase.
Winston A; Stebbing J
J HIV Ther; 2004 May; 9(2):25-7. PubMed ID: 15238872
[No Abstract] [Full Text] [Related]
32. Drug resistance in non-subtype B HIV-1.
Kantor R; Katzenstein D
J Clin Virol; 2004 Mar; 29(3):152-9. PubMed ID: 14962783
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive patients naïve for anti-retrovirals.
Torti C; Bono L; Gargiulo F; Uccelli MC; Quiros-Roldan E; Patroni A; Paraninfo G; Tirelli V; Manca N; De Francesco MA; Perandin F; Carosi G
Clin Microbiol Infect; 2004 Sep; 10(9):826-30. PubMed ID: 15355414
[TBL] [Abstract][Full Text] [Related]
34. Resistance tests: what do clinical trials tell us?
Price N; Smit E; Pillay D
J HIV Ther; 2002 Nov; 7(4):80-6. PubMed ID: 12733605
[TBL] [Abstract][Full Text] [Related]
35. Selection of L74V mutation in reverse transcriptase of HIV-1 subtype D by a tenofovir DF-lamivudine based regimen.
Tamalet C; Tomei C; Henry M; Solas C; Villacian J; Colson P
AIDS; 2007 Nov; 21(18):2551-2. PubMed ID: 18025898
[No Abstract] [Full Text] [Related]
36. The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors.
Parkin NT; Gupta S; Chappey C; Petropoulos CJ
Antimicrob Agents Chemother; 2006 Jan; 50(1):351-4. PubMed ID: 16377709
[TBL] [Abstract][Full Text] [Related]
37. Update of the drug resistance mutations in HIV-1: 2004.
Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
[No Abstract] [Full Text] [Related]
38. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
39. Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre-treated HIV infected patients.
Roquebert B; Wirden M; Simon A; Deval J; Katlama C; Calvez V; Marcelin AG
J Med Virol; 2007 Mar; 79(3):207-11. PubMed ID: 17245724
[TBL] [Abstract][Full Text] [Related]
40. Analysis of drug resistance-associated mutations in treatment-naïve individuals infected with different genetic forms of HIV-1 circulating in countries of the former Soviet Union.
Vázquez de Parga E; Rakhmanova A; Pérez-Alvarez L; Vinogradova A; Delgado E; Thomson MM; Casado G; Sierra M; Muñoz M; Carmona R; Vega Y; Contreras G; Medrano L; Osmanov S; Nájera R
J Med Virol; 2005 Nov; 77(3):337-44. PubMed ID: 16173024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
